Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegaptanib versus sham for diabetic macular edema
2005-001460-32Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2005
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegaptanib sodium in diabetic macular edema (DME) (2 arms), sponsored by Pfizer. Primary endpoint: Proportion of subjects with >10-letter improvement in visual acuity at 1 year. Started Dec 2005; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2005-001460-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001460-32.